Central Nervous System Biomarkers Can Be Used To Check Clinical Utility And Identify The Correct Treatment For The Patient

Central Nervous System Biomarkers

Central Nervous System Biomarkers are molecules that signal the presence of a disease or dysfunction in the body. They are used for diagnosis, monitoring disease progression, and choosing the best treatments.

They are also important in understanding the relationship between diseases and environmental factors, such as smoking, alcohol consumption, and obesity, and in determining subjects who are at high risk for developing disease. These markers help identify the right drug or treatment for a specific patient and can be used in clinical trials to determine if an experimental medicine works.

A growing body of scientific evidence indicates that Central Nervous System Biomarkers related disorders are caused by a combination of damage to the blood-brain barrier (BBB), inflammation, and genetic factors. The development of biomarkers that detect these causes of neurological problems is likely to improve the ability to diagnose, treat, and even prevent them.

The discovery of biomarkers for a growing range of medical disorders is anticipated to propel the Central Nervous System Biomarkers Market.

There are a number of promising BBB biomarkers that can be detected in blood, including neurofilament light (NFL) and protein fragments called peptide-derived oxidative stress (PDOPS). These markers are available through Quanterix, whose technology can multiplex up to 1,000 biomarkers in less than one drop of blood.

Inflammation and Central Nervous System Biomarkers related disorders are often associated with aging, so the ability to identify and monitor these conditions is crucial for assessing the efficacy of therapeutics. Cytokines are a key component of inflammation in the body, and recent studies have linked elevated levels to depression, autism, and schizophrenia.

Another promising marker for CNS-related disorders is the enzyme NSE, which resides in neurons and glial cells. Elevated NSE levels are thought to indicate oxidative damage in neurons and abnormal activation of microglia, astrocytes, and other specialized cells.

The Paediatric Medical Devices Market is expected to grow at a CAGR of 8.7% between 2022 and 2028, from a value of US$ 31,726.3 Mn in 2021 to US$ 57,035.3 Mn by 2028.

While NSE is a commonly used biomarker for inflammation, it is only recently being recognized as a viable indicator of CNS-related disorders. Researchers have found that the NSE level in blood is a good predictor of whether or not a person has suffered a head injury and that patients with chronic traumatic encephalopathy (CTE) have higher NSE levels than healthy controls.

Novartis Pharma AG and Siemens Healthineers signed a master partnership agreement in September 2020, for creating and developing the market diagnostic tests for Novartis' medicinal portfolio.